caa a22 4500 467935017 CHVBK 20180406152954.0 cr unu---uuuuu 170328e20061001xx s 000 0 eng 10.1007/s00408-005-2591-y doi (NATIONALLICENCE)springer-10.1007/s00408-005-2591-y The Role of c-erbB-2 Expression on the Survival of Patients with Small-Cell Lung Cancer [Elektronische Daten] [Ozlem Canoz, Metin Ozkan, Vedat Arsav, Ozlem Er, H. Coskun, Serdar Soyuer, Mustafa Altinbas] The aim of this study was to determine the incidence and role of c-erbB-2 overexpression as a predictive/prognostic marker in small-cell lung carcinoma (SCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of SCLC. A chart review for demographic and clinical data was performed on patients with SCLC diagnosed between 1998 and 2004. c-erbB-2 overexpression was evaluated using immunohistochemistry performed on archival paraffin-embedded specimens. Sixty-seven patients with SCLC were identified (6 females, 61 males; median age- 56.5 yr, range-34-75) all of whom had adequate tissue specimens available for c-erB-2 testing. Of the 67 specimens, 12 (17.9%) showed c-erbB-2 overexpression. Seventy-five of the cases were positive for c-erbB-2, had extensive disease. The median overall survival of patients with SCLC whose tumors were positive and negative for c-erbB-2 were 8 ± 0.9 months (95%CI 6.3-9.7) and 11 ± 1.5 months (95%CI 8.0-14.0), respectively. c-erbB-2 overexpression detected using immunohistochemistry is observed in 17.9% of patients with SCLC and has statistically significant prognostic value. Our findings suggest that c-erbB-2 may be a potential target for site-specific immunotherapy in SCLC. Considering one technique examined, further molecular investigation is needed to confirm these preliminary findings. Springer Science+Business Media, Inc., 2006 Small-cell lung careinoma nationallicence c-erbB-2 nationallicence Prognosis nationallicence Canoz Ozlem MKP Blv Hukukcular Sit. B-Blok No. l5 Kocasinan, 38090, Kayseri, Turkey aut Ozkan Metin Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut Arsav Vedat Department of Pathology, Erciyes University Medical Faculty, Kayseri, Turkey aut Er Ozlem Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut Coskun H. Department of Medical Oncology, Suleyman Demirel University Medical Faculty, Toparta, Turkey aut Soyuer Serdar Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut Altinbas Mustafa Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut Lung Springer-Verlag; www.springer-ny.com 184/5(2006-10-01), 267-272 0341-2040 184:5<267 2006 184 408 https://doi.org/10.1007/s00408-005-2591-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00408-005-2591-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Canoz Ozlem MKP Blv Hukukcular Sit. B-Blok No. l5 Kocasinan, 38090, Kayseri, Turkey aut NATIONALLICENCE 700 1- Ozkan Metin Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut NATIONALLICENCE 700 1- Arsav Vedat Department of Pathology, Erciyes University Medical Faculty, Kayseri, Turkey aut NATIONALLICENCE 700 1- Er Ozlem Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut NATIONALLICENCE 700 1- Coskun H. Department of Medical Oncology, Suleyman Demirel University Medical Faculty, Toparta, Turkey aut NATIONALLICENCE 700 1- Soyuer Serdar Department of Radiation Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut NATIONALLICENCE 700 1- Altinbas Mustafa Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey aut NATIONALLICENCE 773 0- Lung Springer-Verlag; www.springer-ny.com 184/5(2006-10-01), 267-272 0341-2040 184:5<267 2006 184 408 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer